You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Dow
Mallinckrodt
Colorcon
Express Scripts

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Infliximab - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for infliximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Shanghai Mental Health CenterN/A
National Institute for Tuberculosis and Lung Diseases, PolandPhase 4
Hull and East Yorkshire Hospitals NHS TrustPhase 2

See all infliximab clinical trials

Recent Litigation for infliximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.2019-12-31
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all infliximab litigation

PTAB Litigation
PetitionerDate
Dr. Reddy's Laboratories, Inc.2018-08-03
2014-11-06

See all infliximab litigation

Pharmacology for infliximab

Patent Text Search: US Patents for infliximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for infliximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
0868 Netherlands   Start Trial PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707
0170010 00272 Estonia   Start Trial PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
2010000047 Germany   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
2016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
757 Luxembourg   Start Trial 91757, EXPIRES: 20250526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKesson
Mallinckrodt
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.